BioSpace News Archive

Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference: Participation starting on Monday, November 29.

MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December 2, 2021.

Pear Therapeutics, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD).

The Institute for Molecular Medicine (IMM), a non-profit research organization established in 1996 with the goal of understanding, preventing, and curing chronic diseases, including neurodegenerative disorders, today announced that it has been awarded an additional $3 million to the previously awarded $4.7 million grant from the National Institutes of Aging (NIA) of the NIH.

Numinus Wellness Inc. will release its financial results for the quarter and year ended August 31, 2021 after market close on Thursday, December 9, 2021.

Vapotherm, Inc. today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021.

Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces topline results from its Phase 1b multiple ascending dose trial with dapiglutide.

Halberd Corporation (OTC Pink: HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.